Skip to main
SNTI

SNTI Stock Forecast & Price Target

SNTI Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Senti Biosciences Inc. has demonstrated significant advancements in its lead CAR-NK therapy, SENTI-202, showing a complete response rate of 42% in its phase I study for relapsed/refractory AML, indicating promising efficacy and potential for durable responses in a broad patient population. The receipt of Regenerative Medicine Advanced Therapy (RMAT) designation positions the company favorably for streamlined FDA engagement as it prepares for pivotal trials scheduled to begin in 2026, enhancing its regulatory outlook. Overall, the increase in the probability of success for its programs, coupled with the encouraging clinical data, contributes to a positive outlook for Senti Biosciences's stock.

Bears say

Senti Biosciences is facing potential downward revisions to its risk-adjusted projections and price target, indicating a concerning outlook for its financial health. These anticipated adjustments suggest that the company's current and future financial performance may not meet market expectations. Additionally, the repeated emphasis on possible downward revisions highlights significant uncertainty surrounding Senti Biosciences' product developments and their respective impacts on revenue generation.

SNTI has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Senti Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Senti Biosciences Inc (SNTI) Forecast

Analysts have given SNTI a Strong Buy based on their latest research and market trends.

According to 4 analysts, SNTI has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Senti Biosciences Inc (SNTI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.